Skip to main navigation
close search window
Cingulate Therapeutics LogoCingulate Therapeutics Logo
Connect With Us
Header Menu
  • Company
    • About Cingulate®
    • Senior Management
    • Board of Directors
    • Scientific Advisors
  • Patient Experience
    • Patient Experience
    • Treatments
  • Pipeline
    • Pipeline Overview
    • Cingulate® Technology
    • CTx-1301
    • CTx-1302
    • Publications
  • Partners
  • Press Releases
  • Investors
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
      • SEC Filings
    • Analyst Coverage
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
    • IR Resources
      • Investor FAQs
      • Email Alerts
      • Contact IR
  • Careers
  • Contact Us
Header Social TwitterLinkedIn
Header Menu
  • Company
    • About Cingulate®
    • Senior Management
    • Board of Directors
    • Scientific Advisors
  • Patient Experience
    • Patient Experience
    • Treatments
  • Pipeline
    • Pipeline Overview
    • Cingulate® Technology
    • CTx-1301
    • CTx-1302
    • Publications
  • Partners
  • Press Releases
  • Investors
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
      • SEC Filings
    • Analyst Coverage
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
    • IR Resources
      • Investor FAQs
      • Email Alerts
      • Contact IR
  • Careers
  • Contact Us
back to top
close search window
Search:
search submit button
 

Press Release

Jan 13, 2018 Pharmacoscintigraphic and Pharmacokinetic Analysis of CTx 1301, a Novel Trimodal Oral Formulation for Release of Dexmethylphenidate in Healthy Adults

Presented at 2018 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting.

DOWNLOAD POSTER

CTx®_4C
TwitterLinkedIn

Contact us

1901 W 47th Place
Kansas City 66205

 

info@cingulate.com
913-942-2300

© Cingulate® |  PRIVACY POLICY